Agonists of PPARs and FXR have been investigated extensively in mouse models (69, 70), clinical trials presently are ongoing to test the effects of these drugs for potential NASH treatments. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.